Medindia

X

Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008

Tuesday, December 9, 2008 General News J E 4
Advertisement
ROCKVILLE, Md., Dec. 8 Novavax, Inc.(Nasdaq: NVAX) today announced that the Company will hold an investorconference call to discuss results from its Phase II human clinical trial inhealthy adult subjects of Novavax's seasonal influenza VLP vaccine candidateat 11:00 a.m. Eastern Time on December 11, 2008.

The call will be hosted by Novavax President and Chief Executive OfficerDr. Rahul Singhvi and other members of senior management, including ChiefMedical Officer, Dr. Penny Heaton. A question and answer session will followthe presentation of the data. The dial-in number for the conference call isUSA and Canada (866) 814 8448 International: (703) 639 1367

A live audio and presentation webcast of the conference call will beavailable at http://www.novavax.com. Please connect to this website at least15 minutes prior to the conference call to ensure adequate time for anysoftware download that may be needed to hear the webcast. A replay of thewebcast will be available for 90 days after the webcast and a replay of theconference call will also be available by telephone beginning 1pm EST.December 11, 2008 through midnight December 13, 2008. To access the telephonereplay, dial (703) 925 2533 and enter pass code 1313471.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novelvaccines to address a broad range of infectious diseases worldwide usingadvanced proprietary virus-like particle (VLP) technology. The Companyproduces these VLP based, potent, recombinant vaccines utilizing new, andefficient manufacturing approaches. Additional information about Novavax isavailable at http://www.novavax.com and in the Company's various filings withthe Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance,conditions or strategies and other matters, including expectations regardingproduct and clinical developments are forward-looking statements within themeaning of the Private Securities Litigation Reform Act. Novavax cautions thatthese forward-looking statements are subject to numerous assumptions, risksand uncertainties, which change over time. Factors that may cause actualresults to differ materially from the results discussed in theforward-looking statements or historical experience include risks anduncertainties, including risks relating to the early stage of Novavax'sproduct candidates under development; current results may not be predictive offuture pandemic results, results of our seasonal influenza vaccine or anyother vaccine that we may develop; further testing is required before FDA canbe applied for and the FDA may not approve the pandemic vaccine even iffurther trial results are similar to those disclosed herein; uncertaintiesrelating to clinical trials; dependence on the efforts of third parties;competition for clinical resources and patient enrollment from drug candidatesin development by other companies with greater resources and visibility; andrisks that we may lack the financial resources and access to capital to fundour operations including further clinical trials. Further information on thefactors and risks that could affect Novavax's business, financial conditionsand results of operations, is contained in Novavax's filings with the U.S.Securities and Exchange Commission, which are available at http://www.sec.gov.These forward-looking statements speak only as of the date of this pressrelease, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Kiadis Pharma Receives Two Orphan Drug Designation...
S
Amylin, Lilly Update on FDA Review of BYETTA(R) (e...